FISCHER MEDICAL VENTURES LTD.
NSE : NABSE : 524743ISIN
CODE : INE771F01025Industry : ChemicalsHouse
: Private
BSE539.7517.8 (+3.41 % )
PREV CLOSE (Rs.) 521.95
OPEN PRICE (Rs.) 498.55
BID PRICE (QTY) 505.55 (1 )
OFFER PRICE (QTY) 538.65 (10 )
VOLUME 74
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE
This Company is not listed in NSE
Company News
| Date | Heading | Details |
|---|---|---|
| 04-May-2024 | Fischer Chemic informs about board meeting | <div>Fischer Chemic has informed that the meeting of the Board of Directors of Fischer Medical Ventures (Formerly known as Fischer Chemic) was held on Saturday 04th May 2024 at the Registered Office of the Company. The outcome is enclosed.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 04-May-2024 | Fischer Chemic informs about outcome of board meeting | <div style="text-align: justify;">Fischer Chemic has informed that the Board of Directors of Fischer Medical Ventures (Formerly known as Fischer Chemic) (‘the Company') in its meeting held at the Registered Office of the Company on Saturday 04th May 2024 have inter-alia considered and approved the following amongst other items: Subsequent to successful completion of the open offer made by Time Medical International Ventures Pte Ltd (Acquirer-1), Shankar Varadharajan (Acquirer-2) and Ravindran Govindan (Acquirer-3) (hereinafter collectively referred to as the Acquirers) in accordance with the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulation, 2011, the Board of Directors induced the Acquirers as the new promoters of the Company; Considered and took on records the resignation of Dilip Suryakant Jha as the Director of the Company with effect from closure of Business hours on 04th May 2024 and he shall continue as the Chief Financial officer of the Company. Further, details required under Regulation 30 of SEBI Listing Regulations, 2015, are given as Annexure-I.; On the recommendations of the Nomination Remuneration Committee have approved the appointment of Ravindran Govindan (DIN: 03137661) as Chairman and Managing Director of the Company for a term of Five years from 04th May 2024 subject to approval of shareholders in the ensuing Postal Ballot Process. Further, details required under Regulation 30 of SEBI Listing Regulations, 2015, are given as Annexure-II.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 30-Apr-2024 | Open Offer | Inter alia, to consider and approve:- 1. The Change in management of the Company subsequent to completion of open offer in accordance with the provisions of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; 2. The setting up of corporate office Address of the Company in Chennai, Tamil Nadu; and 3. To transact other incidental and ancillary matters as may be decided by the board |
| 18-Apr-2024 | Post Offer Advertisement | Navigant Corporate Advisors Ltd ("Manager to the Offer") has submitted to BSE a copy of Post Offer Advertisement to the equity shareholders of Fischer Chemic Ltd ("Target Company"). |
| 23-Mar-2024 | Fischer Chemic informs about details of loss of certificate | <div style="text-align: justify;">Fischer Chemic has informed that the company has received request for issuance of Duplicate Share Certificate(s) in lieu of lost/misplaced original Share Certificate(s) from the shareholder/legal heir(s). Name of Shareholder: Vijaya E, Folio No. 016043</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
| 21-Mar-2024 | Updates on Open Offer | Navigant Corporate Advisors Ltd ("Manager to the Offer") has submitted to BSE a copy of Offer Opening Public Announcement to the Shareholders of Fischer ChemicLtd ("Target Company"). |
| 19-Mar-2024 | Outcome Of Meeting Of Committee Of Independent Directors For Open Offer Of Fischer Chemic Limited | Please find enclosed outcome of the Committee of Independent Director for the open offer held on 19th March 2024 |
| 18-Dec-2023 | Fischer Chemic touches roof on getting nod to acquire 100% stake in Time Medical International Ventures | <p style="text-align: justify;">Fischer Chemic is currently trading at upper limit of Rs. 199.70, up by 3.90 points or 1.99% from its previous closing of Rs. 195.80 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 199.70 and has touched a high and low of Rs. 199.70 and Rs. 199.70 respectively. So far 71 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 199.70 on 18-Dec-2023 and a 52 week low of Rs. 66.80 on 04-Oct-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 199.70 and Rs. 161.15 respectively. The current market cap of the company is Rs. 49.93 crore.</p><p style="text-align: justify;">The Non-Institutions held 100.00% stake in the company.</p><p style="text-align: justify;">Fischer Chemic has received approval for acquisition of 100% of the Share Capital of Time Medical International Ventures (India) (Target Company). The Board has approved the execution of a Share Purchase and Share Subscription Agreement between the Company, Time Medical International Ventures (India) and their shareholders (SPSSA) and execution of other necessary documents regarding the Proposed Transaction, whereby the Company agrees to acquire 100% of the share capital of the Target Company.</p><p style="text-align: justify;">With this acquisition, Company will make an entry into the growing market of diagnostic imaging industry with innovative and disruptive technologies. The acquisition will provide access to entirely new business vertical and shall give advantages of complementary skill sets and result in significant benefits such as, greater market penetration, enhanced product offerings and innovative range of products, entry into new markets, new process learnings, availability of highly skilled man power, input cost optimisation and potential sourcing benefits.</p><p style="text-align: justify;">Fischer Chemic is engaged in the trading of certain grades of Laboratory Chemicals.</p> |
| 18-Dec-2023 | Oriental Rail Infrastructure, Shakti Pumps and Adani Enterprises to see some action today | <p style="text-align: justify;"><span style="font-weight: bold;">Oriental Rail Infrastructure </span>has secured order worth Rs 12.14 crore from ‘Modern Coach Factory (MCF), Raebareli, Indian Railways. The order is for Manufacturing and Supplying of 126 sets of ‘Seat and Berths' for LHB AC3T Economy coaches. The said order is to be executed by May 31, 2024.</p><p style="text-align: justify;"><span style="font-weight: bold;">Shakti Pumps (India) </span>has successfully obtained its 8th patent for its ground-breaking pump design for inventing a ‘HELICAL PUMP ASSEMBLY'. The Patent Office, Government of India, has awarded Shakti Pumps this patent, fully adhering to the provisions set forth in the Patents Act of 1970. This patent is set to maintain its validity for duration of 20 years.</p><p style="text-align: justify;"><span style="font-weight: bold;">Adani Enterprises</span>' wholly owned subsidiary -- AMG Media Networks (AMNL) has acquired 50.50% stake constituting Equity Shares (Category I shares - with voting rights) and Equity Shares (Category II shares - without voting rights) each of IANS India (IANS) on December 15, 2023 in accordance with Share Purchase Agreement dated December 15, 2023. The transfer of shares related to the acquisition were approved by the Board of IANS at its meeting held on December 15, 2023. Pursuant to the acquisition as set out above, IANS is now a subsidiary of AMNL. </p><p style="text-align: justify;">General Atlantic has divested around 10 per cent stake in <span style="font-weight: bold;">KFin Technologies</span> for Rs 851 crore through an open market transaction. General Atlantic through its affiliate General Atlantic Singapore Fund Pte sold the shares of the company. The US-based private equity firm is the promoter of KFin Technologies.</p><p style="text-align: justify;"><span style="font-weight: bold;">Zydus Lifesciences </span>(including its subsidiaries/affiliates, hereafter referred to as ‘Zydus') has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg, and 200 mg (USRLD: Vimpat Tablets).</p><p style="text-align: justify;"><span style="font-weight: bold;">IRB Infrastructure Developers</span>' associate company -- IRB Infrastructure Trust has received Letter of Award from National Highways Authority of India (NHAI) for the project of Tolling, Operation, Maintenance and Transfer of Kota Bypass and Cable Stay Bridge on NH-76 (New NH-27) in the state of Rajasthan and Gwalior-Jhansi section from km 0.00 to km 103.000 (revised section Km. 16.000 to Km. 98.455) of NH-75 (New NH-44) in the State of Madhya Pradesh and Uttar Pradesh on Toll Operate and Transfer (TOT) Mode (TOT Bundle 13) (the Project). The IRB Infrastructure Trust to pay upfront Concession Fee of Rs 1,683 crore to NHAI for revenue linked Concession Period of 20 years. </p><p style="text-align: justify;"><span style="font-weight: bold;">Fischer Chemic</span> has received approval for acquisition of 100% of the Share Capital of Time Medical International Ventures (India) (Target Company). The Board has approved the execution of a Share Purchase and Share Subscription Agreement between the Company, Time Medical International Ventures (India) and their shareholders (SPSSA) and execution of other necessary documents regarding the Proposed Transaction, whereby the Company agrees to acquire 100% of the share capital of the Target Company.</p> |
| 16-Dec-2023 | Fischer Chemic gets nod to acquire 100% stake in Time Medical International Ventures | <p style="text-align: justify;">Fischer Chemic has received approval for acquisition of 100% of the Share Capital of Time Medical International Ventures (India) (Target Company). The Board has approved the execution of a Share Purchase and Share Subscription Agreement between the Company, Time Medical International Ventures (India) and their shareholders (SPSSA) and execution of other necessary documents regarding the Proposed Transaction, whereby the Company agrees to acquire 100% of the share capital of the Target Company.</p><p style="text-align: justify;">With this acquisition, Company will make an entry into the growing market of diagnostic imaging industry with innovative and disruptive technologies. The acquisition will provide access to entirely new business vertical and shall give advantages of complementary skill sets and result in significant benefits such as, greater market penetration, enhanced product offerings and innovative range of products, entry into new markets, new process learnings, availability of highly skilled man power, input cost optimisation and potential sourcing benefits.</p><p style="text-align: justify;">Fischer Chemic is engaged in the trading of certain grades of Laboratory Chemicals.</p> |
